Sunshine Biopharma Inc.
SBFMDrugs in Pipeline
41
Phase 3 Programs
18
Upcoming Catalysts
15
Next Catalyst
May 15, 2026
29dMarket Overview
Stock performance and key metrics
15 upcoming, 1 past
Topical corticosteroid
Dermatitis, Atopic
608 Q2W
Psoriasis
DAG181
Chronic HCV Infection
Clascoterone
Acne Vulgaris
Pembrolizumab
Advanced Non-Small Cell Lung Cancer
Lerotinib
Esophageal Cancer
prefilled liquid etanercept(Yisaipu)
Ankylosing Spondylitis
EPREX®
Renal Anemia
HEC74647PA+HEC110114
Chronic HCV Infection
SOF
Chronic HCV Infection
611
Pulmonary Disease, Chronic Obstructive (COPD)
5% minoxidil foam
Androgenetic Alopecia
SSGJ-707
Advanced/recurrent Endometrial Cancer and Platinum-resistant Ovarian Cancer
601 1.25mg
Branch Retinal Vein Occlusion
608 dose
Ankylosing Spondylitis
Clifutinib
Leukemia, Acute Myeloid (AML)
ranibizumab 0.5mg
Branch Retinal Vein Occlusion
610
Asthma
Z650
Esophageal Squamous Cell Carcinoma
626
Systemic Lupus Erythematosus (SLE)
611 Q2W
Dermatitis, Atopic
SSS17
Anemia in Pre-Dialysis Patients
Pemetrexed
First-line Advanced NSCLC Patients
HEC585 dose A
Progressive Fibrosing Interstitial Lung Disease (PF-ILD) / Progressive Pulmonary Fibrosis (PPF)
RTV
Chronic Hepatitis B
Ranibizuman 0.5 mg
Central Retinal Vein Occlusion
Oxaliplatin
Metastatic Colorectal Cancer
HEC110114 Tablet
Chronic Hepatitis C
HEC169096
Advanced Solid Tumor
Clifutinib Besylate
Acute Myeloid Leukemia, Adult
SSGJ-705
Locally Advanced, Recurrent or Metastatic Malignancies
Injection of humanized nerve growth factor (NGF) antibody
Cancer Pain
SSGJ-706
First-line Advanced NSCLC Patients
GLS4
Chronic HBV Infection
Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 100 mg
Gout Arthritis
Recombinant Anti-interleukin-4 Receptor Alpha Monoclonal Antibody Injection (611)
Dermatitis, Atopic
HEC96719
Non-Alcoholic Steatohepatitis
608
Axial Spondyloarthritis
611 150mg
Dermatitis, Atopic
608 Dose A
Ankylosing Spondylitis
611 300 mg Q2W
Pulmonary Disease, Chronic Obstructive
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Topical corticosteroid | Phase 3 | Dermatitis, Atopic | - | - |
608 Q2W | Phase 3 | Psoriasis | - | - |
DAG181 | Phase 3 | Chronic HCV Infection | - | - |
Clascoterone | Phase 3 | Acne Vulgaris | - | - |
Pembrolizumab | Phase 3 | Advanced Non-Small Cell Lung Cancer | - | - |
Lerotinib | Phase 3 | Esophageal Cancer | - | - |
prefilled liquid etanercept(Yisaipu) | Phase 3 | Ankylosing Spondylitis | - | - |
EPREX® | Phase 3 | Renal Anemia | - | - |
HEC74647PA+HEC110114 | Phase 3 | Chronic HCV Infection | - | - |
SOF | Phase 3 | Chronic HCV Infection | - | - |
611 | Phase 3 | Pulmonary Disease, Chronic Obstructive (COPD) | - | - |
5% minoxidil foam | Phase 3 | Androgenetic Alopecia | - | - |
SSGJ-707 | Phase 3 | Advanced/recurrent Endometrial Cancer and Platinum-resistant Ovarian Cancer | - | - |
601 1.25mg | Phase 3 | Branch Retinal Vein Occlusion | - | - |
608 dose | Phase 3 | Ankylosing Spondylitis | - | - |
Clifutinib | Phase 3 | Leukemia, Acute Myeloid (AML) | - | - |
ranibizumab 0.5mg | Phase 3 | Branch Retinal Vein Occlusion | - | - |
610 | Phase 3 | Asthma | - | - |
Z650 | Phase 2 | Esophageal Squamous Cell Carcinoma | - | - |
626 | Phase 2 | Systemic Lupus Erythematosus (SLE) | - | - |
611 Q2W | Phase 2 | Dermatitis, Atopic | - | - |
SSS17 | Phase 2 | Anemia in Pre-Dialysis Patients | - | - |
Pemetrexed | Phase 2 | First-line Advanced NSCLC Patients | - | - |
HEC585 dose A | Phase 2 | Progressive Fibrosing Interstitial Lung Disease (PF-ILD) / Progressive Pulmonary Fibrosis (PPF) | - | - |
RTV | Phase 2 | Chronic Hepatitis B | - | - |
Ranibizuman 0.5 mg | Phase 2 | Central Retinal Vein Occlusion | - | - |
Oxaliplatin | Phase 2 | Metastatic Colorectal Cancer | - | - |
HEC110114 Tablet | Phase 2 | Chronic Hepatitis C | - | - |
HEC169096 | Phase 2 | Advanced Solid Tumor | - | - |
Clifutinib Besylate | Phase 2 | Acute Myeloid Leukemia, Adult | - | - |
SSGJ-705 | Phase 2 | Locally Advanced, Recurrent or Metastatic Malignancies | - | - |
Injection of humanized nerve growth factor (NGF) antibody | Phase 2 | Cancer Pain | - | - |
SSGJ-706 | Phase 2 | First-line Advanced NSCLC Patients | - | - |
GLS4 | Phase 2 | Chronic HBV Infection | - | - |
Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 100 mg | Phase 2 | Gout Arthritis | - | - |
Recombinant Anti-interleukin-4 Receptor Alpha Monoclonal Antibody Injection (611) | Phase 2 | Dermatitis, Atopic | - | - |
HEC96719 | Phase 2 | Non-Alcoholic Steatohepatitis | - | - |
608 | Phase 2 | Axial Spondyloarthritis | - | - |
611 150mg | Phase 2 | Dermatitis, Atopic | - | - |
608 Dose A | Phase 2 | Ankylosing Spondylitis | - | - |
611 300 mg Q2W | Phase 2 | Pulmonary Disease, Chronic Obstructive | - | - |